Gene therapy for advanced dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 55 years or older.
- Your vision in the study eye must be between 20/25 and 20/320.
- You must have geographic atrophy (a specific type of dry AMD) of a certain size, as confirmed by imaging.
- You can join even if you've had previous treatment for AMD, as long as you've been off it for at least 3 months.
- You cannot have had gene therapy or cell therapy before.
- You must not have wet AMD in the study eye or certain other eye conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This study tests a new gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD). It aims to reduce the need for frequent anti-VEGF injections by delivering a long-lasting treatment into the eye.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This study tests a new gene therapy that may slow or stop the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as an injection into the eye and aims to preserve remaining vision.
Hear when a new Dry Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.